Background and aims The Monash Lupus Clinic is Australia’s first multi-disciplinary specialist lupus clinic, which runs in parallel with a clinical registry program providing healthcare quality and outcomes data for research purposes. We aim to provide an overview of the characteristics and longitudinal outcomes of lupus patients treated at the Monash Lupus Clinic over the last ten years.

Methods Outcome measures included disease activity, medication use, damage accrual and other clinically-relevant events.

Results Over the last 10 years, we have observed improvements in indices associated with better healthcare quality. We observed a significant reduction in the proportion of patients with a maximum SLEDAI-2K score ≥10 over time (chi² test for trend, p<0.001), and a significant trend of an increase in the proportion of patients spending >50% of their observed time meeting the criteria for LLDAS (chi² test for trend, p=0.005). There was also a reduction in the proportion of patients experiencing at least one mild/moderate flare (p<0.001) or severe flare (p=0.006). We also observed a change in the medication use over the last 10 years, with a notable reduction in the use of higher doses of prednisolone (≥7.5 mg/day; p=0.014).

Conclusions Running a multi-disciplinary clinic alongside research activity is both feasible and worthwhile. Systematic collection of longitudinal data on SLE patients has shown changes that reflect better control of disease. As more targeted therapies become available for the treatment of lupus, we expect that such registry data will provide valuable real world evidence of the effectiveness of treatments and management strategies.

Background and aims Systemic Lupus Erythematosus (SLE) is a multisystem disease and patients may benefit from non-pharmacological interventions. We explored the utility of the LupusQol in identifying patients who may benefit from physical, occupational and/or psychological support dependent on the domains affected.

Results 40 patients (97.5% females, 75% Caucasians; 17.5% South-Asians; 5% Afro-Caribbean; mean age 52.2 years) completed the LupusQol over 6 months. Table 1 shows the number of patients who were eligible, the numbers who were referred and the numbers who attended the different support services. All domains of the LupusQol were impaired, with fatigue (45.19) being the worst affected and emotional health (68.60) being the least.

Conclusions Following attendance for physical, occupational and psychological support, we intend to re-administer the LupusQol to determine if these non-pharmacological interventions have improved HRQoL. The appropriateness of the LupusQol threshold used to identify the intervention need will also be evaluated.